Xenetic Biosciences (XBIO) Competitors $3.76 +0.11 (+3.01%) As of 11:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsShort InterestTrendsBuy This Stock XBIO vs. VYNE, FGEN, RLMD, NAII, DRRX, VVOS, BLRX, BIVI, LPCN, and MTEXShould you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include VYNE Therapeutics (VYNE), FibroGen (FGEN), Relmada Therapeutics (RLMD), Natural Alternatives International (NAII), DURECT (DRRX), Vivos Therapeutics (VVOS), BioLineRx (BLRX), BioVie (BIVI), Lipocine (LPCN), and Mannatech (MTEX). These companies are all part of the "med - drugs" industry. Xenetic Biosciences vs. Its Competitors VYNE Therapeutics FibroGen Relmada Therapeutics Natural Alternatives International DURECT Vivos Therapeutics BioLineRx BioVie Lipocine Mannatech VYNE Therapeutics (NASDAQ:VYNE) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk. Is VYNE or XBIO more profitable? Xenetic Biosciences has a net margin of -142.10% compared to VYNE Therapeutics' net margin of -6,974.55%. Xenetic Biosciences' return on equity of -57.31% beat VYNE Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VYNE Therapeutics-6,974.55% -71.89% -58.94% Xenetic Biosciences -142.10%-57.31%-49.30% Does the media prefer VYNE or XBIO? In the previous week, VYNE Therapeutics had 3 more articles in the media than Xenetic Biosciences. MarketBeat recorded 3 mentions for VYNE Therapeutics and 0 mentions for Xenetic Biosciences. VYNE Therapeutics' average media sentiment score of 1.04 beat Xenetic Biosciences' score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the media. Company Overall Sentiment VYNE Therapeutics Positive Xenetic Biosciences Neutral Which has preferable valuation and earnings, VYNE or XBIO? Xenetic Biosciences has higher revenue and earnings than VYNE Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVYNE Therapeutics$500K40.95-$39.83M-$0.99-1.36Xenetic Biosciences$2.50M2.32-$3.96M-$2.38-1.58 Do institutionals & insiders have more ownership in VYNE or XBIO? 83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 4.8% of VYNE Therapeutics shares are held by company insiders. Comparatively, 14.7% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, VYNE or XBIO? VYNE Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Do analysts rate VYNE or XBIO? VYNE Therapeutics currently has a consensus target price of $6.25, indicating a potential upside of 364.34%. Given VYNE Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe VYNE Therapeutics is more favorable than Xenetic Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Xenetic Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryVYNE Therapeutics beats Xenetic Biosciences on 9 of the 16 factors compared between the two stocks. Get Xenetic Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIO vs. The Competition Export to ExcelMetricXenetic BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.80M$2.37B$5.50B$8.92BDividend YieldN/A1.78%5.24%4.05%P/E Ratio-1.588.9127.1720.13Price / Sales2.32490.31376.8992.89Price / CashN/A21.7726.2128.59Price / Book0.974.537.985.60Net Income-$3.96M$31.26M$3.17B$248.49M7 Day Performance0.29%3.73%3.04%5.85%1 Month Performance22.31%4.42%2.38%7.54%1 Year Performance-14.13%0.36%33.64%20.66% Xenetic Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBIOXenetic Biosciences0.6029 of 5 stars$3.76+3.0%N/A-9.0%$5.80M$2.50M-1.584News CoverageVYNEVYNE Therapeutics3.0699 of 5 stars$1.65+16.2%$6.25+278.8%-29.9%$21.60M$500K-1.6730News CoveragePositive NewsHigh Trading VolumeFGENFibroGen4.6962 of 5 stars$5.30+1.5%$250.00+4,617.0%-70.2%$21.10M$29.62M-2.12570Positive NewsRLMDRelmada Therapeutics4.5912 of 5 stars$0.60-1.6%$5.00+732.9%-79.8%$20.25MN/A-0.2410NAIINatural Alternatives International1.0195 of 5 stars$3.28+1.9%N/A-40.1%$19.90M$113.80M-2.36290Positive NewsGap UpDRRXDURECT0.5424 of 5 stars$0.64+1.4%N/A-51.1%$19.44M$2.03M-4.2380Gap DownVVOSVivos Therapeutics0.7675 of 5 stars$3.16-3.7%$4.82+52.4%+124.8%$19.32M$15.03M-1.83160BLRXBioLineRx2.7115 of 5 stars$4.57+3.2%$26.00+468.9%-80.2%$18.88M$28.94M-0.5240BIVIBioVie0.3699 of 5 stars$0.93-8.4%N/A+98.0%$18.76MN/A-0.1210Gap UpLPCNLipocine1.5828 of 5 stars$3.16-4.0%$9.00+184.8%-57.3%$17.60M$11.20M-3.1010MTEXMannatech0.2822 of 5 stars$9.35+3.9%N/A+20.4%$17.11M$117.87M-93.50250High Trading Volume Related Companies and Tools Related Companies VYNE Competitors FGEN Competitors RLMD Competitors NAII Competitors DRRX Competitors VVOS Competitors BLRX Competitors BIVI Competitors LPCN Competitors MTEX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XBIO) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredA “starter home” for $1925?An MIT startup just slashed the cost of producing the world’s most valuable metal — by 99%. This “miracle m...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XBIO Stock Alerts